Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 15/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2692189 | 0.84 | KDM4E (0.36) | KDM4EAR | |
| SCHEMBL27810310 | 0.81 | KDM4E (0.42) | KDM4ECXCR4TRPV4LMNA | |
| SCHEMBL26150445 | 0.78 | SLC6A4 (0.40) | ARSLC6A4NOS2TRPV4 | |
| SCHEMBL12775303 | 0.78 | AR (0.40) | ARSLC6A4NOS2 | |
| SCHEMBL25415107 | 0.77 | KHK (0.41) | ARSLC6A4NOS2 | |
| SCHEMBL14955073 | 0.77 | TRPV4 (0.39) | ARSLC6A4NOS2TRPV4 | |
| SCHEMBL29480826 | 0.77 | AR (0.41) | ARSLC6A4NOS2 | |
| SCHEMBL14658984 | 0.77 | AR (0.41) | ARSLC6A4NOS2 | |
| SCHEMBL12167442 | 0.77 | SLC6A4 (0.42) | KDM4EARSLC6A4NOS2 | |
| SCHEMBL31042250 | 0.77 | KHK (0.41) | ARSLC6A4NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112437771-B | Bronchodilating heteroatom-linked amides | 阿凯德制药公司 | 2024-06-18 | — | — | CN | disclosed |
| WO-2023114198-A2 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114200-A2 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ALEXION PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-11680054-B2 | Bronchodilating hetero-linked amides | ARCEDE PHARMA AB (SE) | 2023-06-20 | — | — | US | disclosed |
| US-11680054-B2 | Bronchodilating hetero-linked amides | ARCEDE PHARMA AB (SE) | 2023-06-20 | — | — | US | disclosed |
| US-11680054-B2 | Bronchodilating hetero-linked amides | ARCEDE PHARMA AB (SE) | 2023-06-20 | — | — | US | disclosed |
| US-20230000847-A1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | DRAIG THERAPEUTICS LTD (GB) | 2023-01-05 | — | — | US | disclosed |
| US-11298345-B2 | Compounds that modulates AMPA receptor function | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2022-04-12 | — | — | US | disclosed |
| EP-3818055-B1 | NOVEL BRONCHODILATING HETERO-LINKED AMIDES | RESPIRATORIUS AB PUBL (SE) | 2022-02-16 | — | — | EP | disclosed |
| EP-3818055-B1 | NOVEL BRONCHODILATING HETERO-LINKED AMIDES | RESPIRATORIUS AB PUBL (SE) | 2022-02-16 | — | — | EP | disclosed |
| US-9216975-B2 | TRPV1 vanilloid receptor antagonists with a bicyclic portion | Serentrix, LLC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20130079339-A1 | TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION | PHARMESTE S.R.L. (IT) | 2013-03-28 | — | — | US | disclosed |
| US-20120251551-A1 | Substituted (Heteroarylmethyl)thiohydantoins | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| CN-102639523-A | Substituted (heteroarylmethyl) thiohydantoin useful as anticancer agents | BAYER SCHERING PHARMA AG | 2012-08-15 | — | — | CN | disclosed |
| EP-2475653-A1 | SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS | Bayer Pharma Aktiengesellschaft (DE) | 2012-07-18 | — | — | EP | disclosed |
| US-8063078-B2 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | GLAXOSMITHKLINE LLC (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2298757-A2 | Urea compounds active as vanilloid receptor antagonist for the treatment of pain | Glaxo Group Limited (GB) | 2011-03-23 | — | — | EP | disclosed |
| WO-2011029537-A1 | SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-17 | — | — | WO | disclosed |
| US-20090163506-A1 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | SMITHKLINE BEECHAM PLC. (GB) | 2009-06-25 | — | — | US | disclosed |
| EP-2036902-A2 | Urea compounds active as vanilloid receptor antagonist for the treatment of pain | Glaxo Group Limited (GB) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000847-A1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | GRIN1, GRM1, GRIN2A | KDM4E 3845/4885CXCR4 610/4885AR 1881/4885 |
| US-11680054-B2 | Bronchodilating hetero-linked amides | PTGIS, PTGIR, ADRB2 | KDM4E 4068/4885CXCR4 1917/4885AR 1883/4885 |
| US-20120251551-A1 | Substituted (Heteroarylmethyl)thiohydantoins | TPMT, BPHL, VHL | KDM4E 2244/4885CXCR4 4082/4885AR 58/4885 |
| US-20090163506-A1 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | TRPV1, OPRL1, UTS2R | KDM4E 3411/4885CXCR4 652/4885AR 1247/4885 |
| US-11298345-B2 | Compounds that modulates AMPA receptor function | GRIN1, GRM1, GRIN2A | KDM4E 3845/4885CXCR4 610/4885AR 1881/4885 |
| US-20130079339-A1 | TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION | TRPV1, TRPV5, TRPV3 | KDM4E 3115/4885CXCR4 365/4885AR 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.